Related references
Note: Only part of the references are listed.Chronic Myeloid Leukemia in Children Clinical Findings, Management, and Unanswered Questions
Nobuko Hijiya et al.
PEDIATRIC CLINICS OF NORTH AMERICA (2015)
Growth deceleration in children treated with imatinib for chronic myeloid leukaemia
Frederic Millot et al.
EUROPEAN JOURNAL OF CANCER (2014)
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia
Domenico Russo et al.
BLOOD (2013)
Prospective Histomorphometric and DXA Evaluation of Bone Remodeling in Imatinib-Treated CML Patients: Evidence for Site-Specific Skeletal Effects
Kate Vandyke et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
TK Inhibitor Treatment Disrupts Growth Hormone Axis: Clinical Observations in Children with CML and Experimental Data from a Juvenile Animal Model
A. Ulmer et al.
KLINISCHE PADIATRIE (2013)
Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib
Sofia Jonsson et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty
F. Giona et al.
HAEMATOLOGICA (2012)
Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment
Bernadette Anna Sophia Jaeger et al.
MEDICAL SCIENCE MONITOR (2012)
Imatinib has adverse effect on growth in children with chronic myeloid leukemia
Deepak Bansal et al.
PEDIATRIC BLOOD & CANCER (2012)
Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia
Maynika V. Rastogi et al.
PEDIATRIC BLOOD & CANCER (2012)
Management of Chronic Myeloid Leukemia in Childhood
Meinolf Suttorp et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2012)
Imatinib Mesylate Does Not Increase Bone Volume In Vivo
Susannah O'Sullivan et al.
CALCIFIED TISSUE INTERNATIONAL (2011)
Distinct Impact of Imatinib on Growth at Prepubertal and Pubertal Ages of Children with Chronic Myeloid Leukemia
Haruko Shima et al.
JOURNAL OF PEDIATRICS (2011)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
Acquired Growth Hormone Deficiency in a Girl With Chronic Myelogenous Leukemia Treated With Tyrosine Kinase Inhibitor Therapy
Susan L. Hobernicht et al.
PEDIATRIC BLOOD & CANCER (2011)
Gavage-Related Reflux in Rats: Identification, Pathogenesis, and Toxicological Implications (Review)
Siegrid Damsch et al.
TOXICOLOGIC PATHOLOGY (2011)
Receptor tyrosine kinase inhibition causes simultaneous bone loss and excess bone formation within growing bone in rats
Mirja Nurmio et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2011)
Dysregulation of bone remodeling by imatinib mesylate
Kate Vandyke et al.
BLOOD (2010)
Guidelines for Assessment of Bone Microstructure in Rodents Using Micro-Computed Tomography
Mary L. Bouxsein et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Validation of an HPLC Method for Determination of Imatinib Mesylate in Rat Serum and Its Application in a Pharmacokinetic Study
Girish Bende et al.
JOURNAL OF CHROMATOGRAPHIC SCIENCE (2010)
Decreased Bone Turnover Despite Persistent Secondary Hyperparathyroidism during Prolonged Treatment with Imatinib
Susannah O'Sullivan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Long-Term Marginal Zinc Supply Is Not Detrimental to the Skeleton of Aged Female Rats
Reinhold G. Erben et al.
JOURNAL OF NUTRITION (2009)
Imatinib mesylate causes growth plate closure in vivo
K. Vandyke et al.
LEUKEMIA (2009)
Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia
Sofia Jonsson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Long-term imatinib therapy promotes bone formation in CML patients
Stephen Fitter et al.
BLOOD (2008)
Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms
Susannah O'Sullivan et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response
S. Osorio et al.
AMERICAN JOURNAL OF HEMATOLOGY (2007)
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Stephane Picard et al.
BLOOD (2007)
Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism
Andrew Grey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Imatinib mesylate (Gleevec®) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity
Iman El Hajj Dib et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA)
Wataru Ando et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2006)
Imatinib as a potential antiresorptive therapy for bone disease
Andrea L. Dewar et al.
BLOOD (2006)
Altered bone and mineral metabolism in patients receiving imatinib mesylate
E Berman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Inhibition of c-fms by imatinib - Expanding the spectrum of treatment
AL Dewar et al.
CELL CYCLE (2005)
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients
B Peng et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Absolute bioavailability of imatinib (Glivec®) orally versus intravenous infusion
B Peng et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations
E Schleyer et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2004)
Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study
MA Champagne et al.
BLOOD (2004)
Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors
AL Dewar et al.
LEUKEMIA (2003)
Food intake, water intake, and drinking spout side preference of 28 mouse strains
AA Bachmanov et al.
BEHAVIOR GENETICS (2002)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
